Medical equipment industry
Boston Scientific Corp., a leading medical equipment manufacturer, has issued a recall for 200 of its recently approved drug-coated coronary stents due to a malfunction that has been linked to at least one death. The company attributed the defect to a manufacturing issue that has since been addressed. The recalled
Medical equipment industry
Boston Scientific Corporation has announced its financial results for the second quarter of 2004, showcasing impressive growth across all its businesses and regions. Net sales increased by 71% to $1.460 billion, with a conversion rate to drug-eluting stents in the United States reaching over 80% by the end of
Medical equipment industry
Boston Scientific Corp. has announced that it has received an Investigational Device Exemption from the U.S. Food and Drug Administration (FDA) to conduct its ATLAS clinical trial, assessing the safety and efficacy of the company's next-generation TAXUS Liberte coronary stent system. The Liberte stent, designed to enhance
Medical equipment industry
Boston Scientific Corp. is facing backlash over the recall of its flagship Taxus drug-coated stent, following reports of malfunctioning devices that have led to several deaths and injuries. The company has received a total of 95 complaints about Taxus stents with balloons that did not deflate properly, with 43 of
Medical equipment industry
Boston Scientific has announced that it is expanding its voluntarily worldwide recall to include certain additional units of its TAXUS Express2 Paclitaxel-Eluting Coronary Stent Systems, due to potential characteristics in the delivery catheters that can impede balloon deflation during a coronary angioplasty procedure. This recall affects approximately 85,000 TAXUS
Medical equipment industry
Biophan Technologies, Inc., a leader in biomedical device safety, has strengthened its intellectual property position and secured a significant partnership with Boston Scientific Corp. The company's innovative solution makes biomedical devices MRI-safe, a critical breakthrough for the medical industry. Michael Weiner, President and CEO of Biophan, highlighted the
Medical equipment industry
StockPickReport.Com, a registered investment advisor, has published short-term stock recommendations for six companies: EMC Corporation (NYSE:EMC), Medtronic Inc. (NYSE:MDT), Allos Therapeutics Inc. (NASDAQ:ALTH), Agere Systems (AMEX:AGRA), Spectrum Signal Processing (NASDAQ:SSPI), and Medtronic Inc. (NYSE:MDT). The recommendations, available for a free trial at http:
Medical equipment industry
Medtronic, a leading medical technology company, and Genzyme, a biotechnology firm, have partnered to accelerate the development of new treatments for cardiovascular disease. The joint venture, MG Biotherapeutics, will leverage the companies' complementary strengths to develop therapies that repair damaged heart tissue and bring innovative biology to bear on
Medical equipment industry
A securities class action lawsuit has been filed on behalf of shareholders who purchased the common stock and other securities of Synovis Life Technologies, Inc. ("Synovis" or the "Company") between October 16, 2003, and May 18, 2004. The lawsuit alleges that defendants violated federal securities laws
Medical equipment industry
Synovis Life Technologies has announced the appointment of David Buche as vice president of Synovis Life Technologies and chief operating officer of the Synovis Surgical Innovations division. In this new role, Buche will oversee all business aspects of the division, including sales, marketing, and operations. He reports directly to Karen
Medical equipment industry
StockPickReport.Com, a registered investment advisor and stock research firm, has made short-term stock recommendations for several prominent companies. The firm, known for its technical analysis and unbiased research, has issued ratings for EMC Corporation, Medtronic Inc, Allos Therapeutics Inc, and Spectrum Signal Processing Inc. Notably, the firm has ranked
Medical equipment industry
Medtronic, a leading medical technology company, and Genzyme, a biotechnology company, have partnered to accelerate the development of new treatments for cardiovascular disease. The joint venture, MG Biotherapeutics, will leverage the companies' expertise in delivery devices, imaging technologies, and biological approaches to cardiac repair. This collaboration aims to bring
